doi:10.3969/j.issn.1673-8640.2017.01.016

Abstract

CLC Number:

R446.1

Figures/Tables 1

References 9

1	何浩明,周育洋,高党. 新编神经系统治疗防治必读[M]. 上海:同济大学出版社,2006:18-19.
2	KWON H M,LEE Y S,BAE H J,et al.Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke[J]. Stroke,2014,45(3):871-873.
3	诸越瑾,张华,姚洪锋. Hcy、MPV、hs-CRP及FIB对急性脑梗死诊断的价值[J]. 检验医学,2015,30(12):1219-1221.
4	中华神经科学会,中华神经外科学会. 各类脑血管疾病诊断要点[J]. 中华神经科杂志,1996,29(6):379-380.
5	姜宇海,王亚平. 冠心病患者同型半胱氨酸的变化及其临床价值[J]. 检验医学,2014, 29(5): 576-577.
6	顾向明,黄阶胜,李莹莹,等. 血清同型半胱氨酸与C反应蛋白在急性脑血管病诊断中的应用[J]. 检验医学, 2015,30(4): 337-340.
7	胡林强,曹亦宾.急性脑梗死与血浆同型半胱氨酸的相关性分析[J].中国医药,2012,7(11):1369-1370.
8	刘桂香,罗南萍,杨道理. 血浆TXB2和6-K-PGF1α测定在脑梗塞患者中的临床意义[J]. 放射免疫学杂志,2000,13(3):172-173.
9	徐晶雪,车显宏,王洋. 高同型半胱氨酸血症与脑梗死的关系探讨[J]. 中国医刊, 2015,6(5):73-75.

组别	例数	Hcy（μmol/L）	TXB2（ng/L）	6-K-PGF1α（ng/L）
正常对照组	35	7.2±3.3	45.6±20.6	21.2±10.6
ACI组
治疗前	50	17.5±7.2^**	105.1±45.0^**	42.5±20.2^*
治疗后恢复良好	45	7.8±3.9^#	48.2±20.9^#	21.9±10.5^#
治疗后恢复不良	5	16.3±6.3^**	102.0±29.3^**	40.5±12.6^*

组别	例数	Hcy（μmol/L）	TXB2（ng/L）	6-K-PGF1α（ng/L）
正常对照组	35	7.2±3.3	45.6±20.6	21.2±10.6
ACI组
治疗前	50	17.5±7.2^**	105.1±45.0^**	42.5±20.2^*
治疗后恢复良好	45	7.8±3.9^#	48.2±20.9^#	21.9±10.5^#
治疗后恢复不良	5	16.3±6.3^**	102.0±29.3^**	40.5±12.6^*

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 9

Related Articles 15

Recommended Articles

Metrics